Intraoperative Strahlentherapie nach stereotaktischer Körperstrahlentherapie und Chemotherapie bei der Behandlung des Pankreas-Adenokarzinoms
Eine Sicherheitsstudie zur intraoperativen Strahlentherapie nach stereotaktischer Körperbestrahlungstherapie und Chemotherapie mit mehreren Wirkstoffen bei der Behandlung von lokalisiertem Pankreas-Adenokarzinom
This study is designed to investigate the safety of intraoperative radiation therapy (IORT) in patients with localized pancreatic cancer undergoing surgical resection after neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT).
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Standard of care treatment for patients with non-metastatic pancreatic adenocarcinoma (PDAC) includes chemotherapy and Stereotactic Body Radiation Treatment (SBRT) followed by surgical resection of the tumor with or without Intra-Operative Radiation Therapy (IORT).
There is some evidence from other research studies suggesting that adding radiation treatment during the surgical resection may improve local control of the cancer. The use of IORT plus surgical resection can be used to treat pancreatic cancer and is done on a case by case basis at Johns Hopkins.
The department of Radiation Oncology has developed a program using a High Dose Rate-IORT (HDR-IORT). The HDR-IORT makes it possible to deliver concentrated radiation dose at the surface of the tumor.
Our team has shown in previous studies that the majority of cancer cells that remain after treatment are located around the area of the pancreas called the "Triangle Volume" (TV). This region contains blood vessels, lymphatic vessels, and nerves, and is at high risk of containing cancer cells. This region is difficult to treat with SBRT alone because of being close to normal, healthy organs. Therefore, this study involves using IORT to treat the TV to a therapeutic radiation dose.
The part of the treatment that is considered research is:
- Giving one dose of 15 Gy during the surgery using IORT to deliver radiation, and
- Targeting the larger area around the pancreas called the TV
The goal of this study is to determine safety of this added treatment which will be assessed at 3 months after the surgery is completed.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21205
- Johns Hopkins Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age > 18 years old
- Resectable/BRPC/LAPC as defined by NCCN guidelines (Figure 1) as follows confirmed via CT, EUS, or other imaging modalities.
- ECOG performance status 0-2
- Subject or authorized representative, has been informed of the nature of the study and has provided written informed consent, approved by the appropriate Institutional Review Board (IRB) of the respective clinical site.
- Candidate for SBRT at JHU
- Upfront treatment with multi-agent chemotherapy
- Candidate for surgical exploration at JHU
Exclusion Criteria:
- Previous thoracic/abdominal radiation therapy
- Unable to receive SBRT at JHU
- Duodenal invasion detected on imaging which would exclude candidacy for SBRT
- Tumor located in pancreatic body or tail
- Unable to undergo Whipple procedure
- Evidence of disease not localized to the pancreas
- Any arterial reconstruction during surgery
- Currently enrolled in another investigational drug or device trial that clinically interferes with this study
- Unable to comply with study requirements or follow-up schedule
- Women of child bearing potential or sexually active fertile men with partners who are women of child bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Sonstiges: Intra Operative Radiation Therapy (IORT) Group
The IORT group is the single arm of this study. Enrolled patients who undergo standard of care treatment will also receive a study treatment of High Dose Rate (HDR) Intra Operative Radiation Therapy. |
After the patient receives standard of care treatment, they will receive a single dose of radiation (15 Gy) at the time the tumor is surgically removed. Surgeons will then place clips along the blood vessels around the surgical area. These clips will be used to confirm (after surgery) that the expected dose of radiation was received during surgery. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Acute post-operative toxicity of targeted IORT
Zeitfenster: 3 months
|
To evaluate acute post-operative toxicity of IORT targeted to the TV in patients with non-metastatic PDAC undergoing surgical resection after neoadjuvant multi-agent chemotherapy and SBRT. |
3 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Late post-operative toxicity of targeted IORT
Zeitfenster: 6 months
|
To evaluate late toxicity of IORT targeted to the TV in patients with non-metastatic PDAC undergoing surgical resection after neoadjuvant multi-agent chemotherapy and SBRT. To evaluate late toxicity (>90 days) of IORT targeted to the TV in patients with non-metastatic PDAC undergoing surgical resection after neoadjuvant multi-agent chemotherapy and SBRT. |
6 months
|
|
Late post-operative toxicity of targeted IORT
Zeitfenster: 12 months
|
To evaluate late toxicity of IORT targeted to the TV in patients with non-metastatic PDAC undergoing surgical resection after neoadjuvant multi-agent chemotherapy and SBRT. To evaluate late toxicity (>90 days) of IORT targeted to the TV in patients with non-metastatic PDAC undergoing surgical resection after neoadjuvant multi-agent chemotherapy and SBRT. |
12 months
|
|
Late post-operative toxicity of targeted IORT
Zeitfenster: 24 months
|
To evaluate late toxicity of IORT targeted to the TV in patients with non-metastatic PDAC undergoing surgical resection after neoadjuvant multi-agent chemotherapy and SBRT. To evaluate late toxicity (>90 days) of IORT targeted to the TV in patients with non-metastatic PDAC undergoing surgical resection after neoadjuvant multi-agent chemotherapy and SBRT. |
24 months
|
|
Late post-operative toxicity of targeted IORT
Zeitfenster: 36 months
|
To evaluate late toxicity of IORT targeted to the TV in patients with non-metastatic PDAC undergoing surgical resection after neoadjuvant multi-agent chemotherapy and SBRT. To evaluate late toxicity (>90 days) of IORT targeted to the TV in patients with non-metastatic PDAC undergoing surgical resection after neoadjuvant multi-agent chemotherapy and SBRT. |
36 months
|
|
Median local-progression free survival (LPFS) from IORT
Zeitfenster: 6 months
|
To determine the median local-progression free survival (LPFS) from time of IORT. |
6 months
|
|
Median local-progression free survival (LPFS) from IORT
Zeitfenster: 12 months
|
To determine the median local-progression free survival (LPFS) from time of IORT. |
12 months
|
|
Median local-progression free survival (LPFS) from IORT
Zeitfenster: 24 months
|
To determine the median local-progression free survival (LPFS) from time of IORT. |
24 months
|
|
Median local-progression free survival (LPFS) from IORT
Zeitfenster: 36 months
|
To determine the median local-progression free survival (LPFS) from time of IORT. |
36 months
|
|
Median overall survival (OS) from IORT
Zeitfenster: 6 months
|
To determine the median overall survival (OS) from time of IORT. |
6 months
|
|
Median overall survival (OS) from IORT
Zeitfenster: 12 months
|
To determine the median overall survival (OS) from time of IORT. |
12 months
|
|
Median overall survival (OS) from IORT
Zeitfenster: 24 months
|
To determine the median overall survival (OS) from time of IORT. |
24 months
|
|
Median overall survival (OS) from IORT
Zeitfenster: 36 months
|
To determine the median overall survival (OS) from time of IORT. |
36 months
|
|
Median progression free survival (PFS) from IORT
Zeitfenster: 6 months
|
To determine the median progression free survival (PFS) from time of IORT |
6 months
|
|
Median progression free survival (PFS) from IORT
Zeitfenster: 12 months
|
To determine the median progression free survival (PFS) from time of IORT |
12 months
|
|
Median progression free survival (PFS) from IORT
Zeitfenster: 24 months
|
To determine the median progression free survival (PFS) from time of IORT |
24 months
|
|
Median progression free survival (PFS) from IORT
Zeitfenster: 36 months
|
To determine the median progression free survival (PFS) from time of IORT |
36 months
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Amol Narang, MD, JHU, School of Medicine, SKCCC
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- J21105
- IRB00294801 (Andere Kennung: Johns Hopkins Medicine)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .